McKesson Corporation (MCK)
| Market Cap | 101.32B +22.8% |
| Revenue (ttm) | 410.98B +8.8% |
| Net Income | 4.59B +45.1% |
| EPS | 37.48 +50.2% |
| Shares Out | 116.59M |
| PE Ratio | 23.18 |
| Forward PE | 18.70 |
| Dividend | $3.76 (0.43%) |
| Ex-Dividend Date | Sep 1, 2026 |
| Volume | 614,387 |
| Open | 859.74 |
| Previous Close | 856.69 |
| Day's Range | 852.99 - 869.79 |
| 52-Week Range | 661.69 - 999.00 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 991.40 (+14.09%) |
| Earnings Date | Aug 5, 2026 |
About MCK
McKesson Corporation provides healthcare services in the United States and internationally. It operates through four segments: North American Pharmaceutical, Oncology & Multispecialty, Prescription Technology Solutions, and Medical-Surgical Solutions. The company distributes branded, generic, specialty, biosimilar and over-the-counter pharmaceutical drugs, and other healthcare-related products; delivers products to retail pharmacies, hospitals, long-term care centers, clinics, and institutions; and provides logistics and distribution services f... [Read more]
Financial Performance
In fiscal year 2026, McKesson's revenue was $403.43 billion, an increase of 12.36% compared to the previous year's $359.05 billion. Earnings were $4.76 billion, an increase of 44.52%.
Financial StatementsAnalyst Summary
According to 17 analysts, the average rating for MCK stock is "Buy." The 12-month stock price target is $991.4, which is an increase of 14.09% from the latest price.
News
McKesson price target raised to $933 from $812 at Wells Fargo
Wells Fargo raised the firm’s price target on McKesson (MCK) to $933 from $812 and keeps an Equal Weight rating on the shares. The firm is increasing estimates following constructive…
McKesson price target raised to $977 from $966 at Morgan Stanley
Morgan Stanley analyst Erin Wright raised the firm’s price target on McKesson (MCK) to $977 from $966 and keeps an Overweight rating on the shares.
McKesson price target raised to $1,015 from $955 at Baird
Baird raised the firm’s price target on McKesson (MCK) to $1,015 from $955 and keeps an Outperform rating on the shares. The firm updated its model following quarterly results which…
McKesson price target raised to $1,000 from $860 at Evercore ISI
Evercore ISI raised the firm’s price target on McKesson (MCK) to $1,000 from $860 and keeps an Outperform rating on the shares.
McKesson price target raised to $1,006 from $989 at TD Cowen
TD Cowen raised the firm’s price target on McKesson (MCK) to $1,006 from $989 and keeps a Buy rating on the shares. The firm updated its model following a strong…
McKesson price target raised to $1,080 from $1,050 at UBS
UBS raised the firm’s price target on McKesson (MCK) to $1,080 from $1,050 and keeps a Buy rating on the shares.
McKesson price target raised to $905 from $885 at Mizuho
Mizuho analyst Steven Valiquette raised the firm’s price target on McKesson (MCK) to $905 from $885 and keeps a Neutral rating on the shares.
McKesson raises annual profit forecast on strong growth in specialty drug business
Drug distributor McKesson on Wednesday raised its annual profit forecast after beating first-quarter earnings estimates, on strength in its oncology and specialty drug businesses.
McKesson Earnings Call Transcript: Q1 2027
Q1 2027 saw 8% revenue growth to $105.4B and 20% adjusted EPS growth, with all major segments delivering double-digit operating profit increases. Full-year EPS guidance was raised, supported by strong fundamentals, robust specialty and technology-driven growth, and continued capital returns.
McKesson Earnings release: Q1 2027
McKesson released its Q1 2027 earnings on August 5, 2026, summarizing the period's financial results.
McKesson Slides: Q1 2027
McKesson has posted slides in relation to its Q1 2027 quarterly earnings report, which was published on August 5, 2026.
McKesson Quarterly report: Q1 2027
McKesson has published its Q1 2027 quarterly earnings report on August 5, 2026.
McKesson reports Q1 adjusted EPS $9.93, consensus $9.54
Reports Q1 revenue $105.4B, consensus $103.74B. “McKesson (MCK) delivered a strong start to fiscal 2027, underscored by momentum across the enterprise and disciplined execution against our strategic p...
McKesson raises FY27 adjusted EPS view to $44.20-$45 frorm $43.80-$44.60
Consensus $44.25. “The raise in full year Adjusted Earnings per Diluted Share outlook reflects strong first quarter performance and sustainable operational momentum. Our confidence in the business is ...
McKesson Reports Fiscal 2027 First Quarter Results and Raises Full Year Adjusted EPS Guidance
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2027 first quarter financial results. Results can be accessed on McKesson's Investor Relations website at inves...
Healthcare Stocks Have Been Forgotten. Eli Lilly, McKesson, and 9 More to Buy.
A few sectors have dominated the market this year, and healthcare isn't one of them. Many stocks in the sector look ready to gain.
McKesson price target raised to $1,000 from $945 at Citi
Citi raised the firm’s price target on McKesson (MCK) to $1,000 from $945 and keeps a Buy rating on the shares.
McKesson board increases quarterly dividend 15% to 94c per share
The Board of Directors of McKesson (MCK) Corporation declared a regular dividend of $0.94 per share of common stock, a 15% increase from $0.82 per share in the prior quarter.
McKesson Corporation Raises Quarterly Dividend by 15% to $0.94 Per Share
IRVING, Texas--(BUSINESS WIRE)--The Board of Directors of McKesson Corporation (NYSE:MCK) yesterday declared a regular dividend of $0.94 per share of common stock, a 15% increase from $0.82 per share ...
McKesson price target raised to $925 from $900 at BofA
BofA raised the firm’s price target on McKesson (MCK) to $925 from $900 and keeps a Buy rating on the shares. The firm is applying a higher target multiple to…
McKesson price target lowered to $989 from $1,012 at TD Cowen
TD Cowen lowered the firm’s price target on McKesson (MCK) to $989 from $1,012 and keeps a Buy rating on the shares. The firm believes McKesson will offer “meaningful concessions”…
McKesson Proxy statement: Proxy filing
McKesson filed a proxy statement on June 30, 2026, providing details for shareholder voting and corporate governance matters.
How High Can the Price of McKesson Stock (MCK) Rise? One Top Analyst Says a 35% Upside Is Possible
McKesson stock gained on Wednesday and one Wall Street analysts expects the shares to continue to rally.
McKesson Corporation Announces First Quarter Fiscal 2027 Earnings Release Date
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) will release its first quarter fiscal 2027 financial results after market close on Wednesday, August 5, 2026. The company will host a l...